The Solaris DE Endoprosthesis for the Treatment of AV Access Stenosis or Occlusion (DEScover)

Prospective, Randomized, Controlled, Multicenter Study of the Solaris DE Endoprosthesis in the Treatment of Venous Outflow Stenosis or Occlusion in Hemodialysis Patients

The goal of this clinical trial is to demonstrate the safety and efficacy of Solaris DE Endoprosthesis in the treatment of stenosis or occlusion within the outflow circuit of the dialysis access including arteriovenous (AV) fistula and synthetic AV graft.

Participants will be treated with Solaris DE Endoprosthesis. Researchers will compare the treatment with investigational product to Percutaneous Transluminal Angioplasty (PTA) alone within the AV fistula cohort in order to demonstrate superiority of Solaris DE.

Study Overview

• Status: Recruiting
• Conditions: Chronic Renal Failure; Venous Stenosis; Venous Occlusion
• Intervention / Treatment: Device: Solaris DE; Device: PTA

Detailed Description

This is a prospective, randomized (1:1), controlled, multicenter study to investigate the safety and efficacy of the Solaris DE Endoprosthesis in the treatment of hemodialysis patients with stenosis or occlusion of the venous outflow circuit. The study population includes two cohorts:

• AVF cohort: participants presenting an arteriovenous fistula (AVF) stenosis or occlusion of the peripheral venous outflow circuit, including the cephalic arch, will be randomized 1:1 between treatment with the test device (Solaris DE) or standard treatment by Percutaneous Transluminal Angioplasty (PTA) alone);
• AVG cohort: participants with an arteriovenous graft (AVG) presenting stenosis or occlusion at the graft vein anastomosis or juxta-anastomosis or at the segment of the prosthesis exit circuit, will be treated with the test device (Solaris DE) only.

• Study Type: Interventional
• Enrollment (Estimated): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Luciano A Curado; Phone Number: +55 62 3625-5027; Email: lcurado@scitechmed.com
• Study Contact Backup: Name: Ana Paula B Almeida, MSc.; Phone Number: +55 62 3625-5027; Email: aalmeida@scitechmed.com

Study Locations

• Brazil
  • Estado de Bahia
    • Salvador, Estado de Bahia, Brazil, 40323-010
      • Recruiting
      • Hospital Ana Nery
      • Principal Investigator: Leonardo Cortizo, MD
      • Contact: Leonardo Cortizo, MD
  • Federal District
    • Brasília, Federal District, Brazil, 70390-150
      • Recruiting
      • Afya Hospital Dia LTDA
      • Principal Investigator: Thiago Barroso, MD
      • Contact: Thiago A Barroso, MD
  • Minas Gerais
    • Belo Horizonte, Minas Gerais, Brazil, 30130-100
      • Recruiting
      • Hospital das Clínicas da UFMG/EBSERH
      • Contact: Guilherme Castro, MD
      • Principal Investigator: Guilherme Castro, MD
  • Pernambuco
    • Recife, Pernambuco, Brazil, 52010-160
      • Recruiting
      • Real Hospital Português de Beneficência em Pernambuco
      • Principal Investigator: Douglas Cavalcanti, MD
      • Contact: Douglas Cavacanti, MD
  • Rio de Janeiro
    • Rio de Janeiro, Rio de Janeiro, Brazil, 20551030
      • Recruiting
      • Hospital Universitario Pedro Ernesto - UERJ
      • Contact: Leonardo O Harduin, MD
      • Principal Investigator: Leonardo O Harduin, MD

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• The participant has a mature AV Fistula (AVF) or Graft (AVG) in the arm created ≥ 30 days before the initial procedure and is in use for dialysis therapy
• The participant has clinical and/or hemodynamic evidence of a venous outflow obstruction or AV fistula or graft dysfunction. The stenotic lesion is ≥ 50%, with a maximum length of 8 cm and a distal reference vessel diameter from 4.0 mm to 9.0 mm
• The participan provides written informed consent prior to any study-specific procedure
• The participan is willing to undergo all follow-up evaluations according to the specified schedule over 24 months

Angiographic Inclusion Criteria:

• The target lesion originates ≥ 3 cm from the cannulation segment (needling zone)

• The target lesion is located:

  1. In one arm (including the cephalic arch) in a participant with AVF, and not in the cannulation segment, OR
  2. In the anastomosis or juxta-anastomosis in a participant with AVF (a juxta-anastomosis is defined as a location where the stent crosses the venous anastomosis)
• The target lesion includes a de novo stenotic lesion or restenosis
• The target lesion is ≥ 5 cm from the arterial anastomosis
• The target lesion has ≥ 50% stenosis according to the operator's visual judgment
• The distal reference vessel diameter of the target lesion is between 4.0 mm and 9.0 mm by the operator's visual judgment
• Single or multiple target lesions measuring ≤ 8 cm in total length by the operator's visual judgment
• Single or multiple target lesions should be covered by a single stent or multiple overlapping stents, provided they are treated as a single lesion with a maximum length of 8 cm
• Successful target lesion pre-dilatation is defined as crossover of the guidewir resulting in full expansion of the pre-dilatation balloon
• The participant has up to 1 (one) non-target lesion in the access circuit requiring intervention in the initial procedure. The non-target lesion must be at least 10 cm away from the target lesion. The non-target lesion can only be treated with standard PTA alone
• Does not have stent implanted or it has been in the access circuit for ≥ 30 days since placement and patent with ≤ 30% stenosis and located ≥ 5 cm from the target lesion
• The non-target lesion must be successfully treated at the time of the initial procedure (success measured as ≤30% residual stenosis and no complications).

Exclusion Criteria:

• Pregnant, breastfeeding or with intention to become pregnant in the next year
• The participant has any major endovascular or surgical procedure planned (including in the access circuit) within 30 days of the initial procedure
• It was not possible to pre-dilate the lesion to be treated with Solaris DE
• Planned surgical revision of the access site
• Known or suspected infection of the hemodialysis access site, systemic infection and/or sepsis
• Patients on immunosuppressive therapy
• Known active coagulopathy or bleeding diathesis
• Known hypersensitivity to nickel titanium alloy, contrast or sirolimus
• Contraindication to antiplatelet, anticoagulant or thrombolytic therapies
• Known allergy to contrast agents or medications administered to perform endovascular intervention that cannot be adequately premedicated
• Life expectancy of less than 12 months
• Has a stent or endoprosthesis located anywhere in the AV access circuit that is not patent (> 30% stenosis) or implanted < 30 days
• The participant's hemodialysis access is expected to be abandoned within 6 months
• The participantis is enrolled in another trial involving an investigational product (pharmaceutical, biological or medical device)
• The patient has a permanent central venous catheter (CVC) for dialysis access, except when its use is temporary, as a bridge to treatment through the access circuit, with a plan for removal after a successful dialysis session after the initial procedure

Angiographic Exclusion Criteria:

• The target lesion is located inside an endoprosthesis
• Target lesion treatment would involve the cannulation segment (needling zone)
• The target lesion is < 5 cm from the arterial anastomosis
• There was a dissection or rupture of the treated vessel during the initial treatment that could not be controlled
• Evidence of an aneurysm, pseudoaneurysm or acute thrombus (i.e. one that has been treated ≤ 15 days) within the target lesion

• The target lesion is, and/or Solaris DE would be placed anywhere:

  1. Through the elbow
  2. In a region that causes bending of the endoprosthesis or bony protrusion over it
  3. In the cannulation segment (needling zone)
  4. Inside any part of a pre-existing stent or endoprosthesis (apart from an access arteriovenous graft)
  5. Lower extremity
  6. Non-synthetic graft
  7. Central thoracic veins located proximal to the cephalic vein arch
• The target lesion is located in such a way that the insertion of a stent would result in a "kink" area that requires a stent bridge between the Solaris DE and an existing stent or stent graft
• The individual has more than 1 (one) non-target lesion (≥ 50% stenosis) that requires intervention in the initial procedure

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: AVF Treatment; Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.	Device: Solaris DE; Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.
Sham Comparator: AVF Control; Participants on dialysis via AV fistula will be treated with percutaneous transluminal angioplasty (PTA) alone.	Device: PTA; Percutaneous Transluminal Angioplasty (PTA) in the treated vessel alone.
Experimental: AVG Treatment; Participants on dialysis via AV graft will be treated with percutaneous transluminal angioplasty (PTA) followed by Solaris DE implantation.	Device: Solaris DE; Percutaneous Transluminal Angioplasty (PTA) followed by Solaris DE implantation in the treated vessel.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety Events	Percentage of participants without any safety events affecting the access or venous outflow circuit and resulting in new intervention, hospitalization or death (not including stenosis or thrombosis).	30 days
Target Lesion Primary Patency (TLPP)	Percentage of participants without restenosis or clinically indicated target lesion revascularization or thrombosis.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Target Lesion Primary Patency (TLPP)	Percentage of participants without restenosis or clinically indicated target lesion revascularization or thrombosis.	12 and 24 months
Assisted Target Lesion Primary Patency (aTLPP)	Percentage of participants without uncorrectable occlusion of the target lesion since the procedure.	1, 6, 12 and 24 months
Access Circuit Primary Patency (ACPP)	Percentage of participants without any new venous outflow circuit intervention, thrombosis or access abandonment since the procedure.	1, 6, 12 and 24 months
Cumulative Patency (CP)	Percentage of participants without the access circuit abandonment since the procedure.	1, 6, 12 and 24 months
Procedure and device-related complications	Complication rates related to the procedure and device involving the access circuit.	1, 6, 12 and 24 months

Collaborators and Investigators

• Sponsor: Scitech Produtos Medicos SA
• Investigators: Principal Investigator: Leonardo O Harduin, MD, Hospital Universitário Pedro Ernesto - Universidade do Estado do Rio de Janeiro (HUPE-UERJ); Principal Investigator: Leonardo C Almeida, MD, Hospital Ana Nery; Principal Investigator: Thiago A Almeida, MD, Afya Hospital Dia LTDA; Principal Investigator: Douglas E T Cavalcanti, MD, Real Hospital Português de Beneficência em Pernambuco; Principal Investigator: Guilherme C Santos, MD, Hospital das Clínicas da UFMG/EBSERH

Study record dates

Study Major Dates

• Study Start (Actual): August 30, 2024
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): February 1, 2028

Study Registration Dates

• First Submitted: October 17, 2023
• First Submitted That Met QC Criteria: October 17, 2023
• First Posted (Actual): October 23, 2023

Study Record Updates

• Last Update Posted (Actual): March 17, 2026
• Last Update Submitted That Met QC Criteria: March 13, 2026
• Last Verified: March 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Urogenital Diseases; Pathologic Processes; Male Urogenital Diseases; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Chronic Disease; Disease Attributes; Renal Insufficiency; Renal Insufficiency, Chronic; Pathological Conditions, Signs and Symptoms; Kidney Failure, Chronic
• Other Study ID Numbers: SCI-SD-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No